Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY1225 in Obesity or Overweight
NCT06893016Phase 3Recruiting
- Sponsor
- Raynovent Biotech
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of RAY1225 in obesity, Overweight, sponsored by Raynovent Biotech. Started Jun 2025; status: recruiting.
02
Drugs
RAY1225
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06893016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893016.